A phase I, open-label, single-dose randomized, two-period crossover study to evaluate the relative bioavailability of single oral doses of two different formulations of divarasib (GDC-6036; 200-mg tablet and 400-mg tablet) in healthy subjects
Healthy Volunteers
For the latest version of this information please go to www.forpatients.roche.com